Refine by
Liquid Biopsy Articles & Analysis: Older
11 articles found
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty. In the era of precision oncology, it has become increasingly common for patients diagnosed with cancer to undergo tumor sequencing. Identifying the mutations that make up a tumor’s genomic landscape can help guide selection of targeted therapies and inform ...
In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow. ...
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 20201. At that time, based ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
X-ZELL is collaborating with Singapore General Hospital (SGH) and the National University Hospital Singapore (NUH) to explore how X-ZELL single-cell diagnostics may aid in the early detection of clinically significant prostate cancer in whole blood. The prospectively blinded, 400-patient multi-centre study officially commenced in 2020 and will lay the foundation for the launch of a commercially ...
Data from 144 tissue samples in the feasibility study demonstrated that SubB2M immunohistochemistry detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions. SubB2M-based immunohistochemistry applications represent a new product opportunity for SubB2M in the $1.9b immunohistochemistry market. INOVIQ Ltd (ASX:IIQ) has successfully completed ...
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
A large part of bacterial, archaeal, viral, and fungal microbial taxa consists of the human microbiome. While many of these microorganisms are commensal, some are harmful to humans and many are symbiotic. Our livelihoods are strongly intertwined with the microbes we allocate our bodies with, regardless of whether their appearance is advantageous, insignificant, or harmful. Over the past few ...
VisionGate, a Breakthrough Liquid-biopsy Technology Company, Leads the Battle Against Lung Cancer through Early Detection Technology with a Simple, Non-Intrusive Sputum Test. VisionGate wants you to live your life with peace of mind. That’s why we’ve launched a new website that makes it easy for you to learn more about our advanced lung cancer detection technology. Our new site ...
NEW YORK - Spanish cancer research firm Universal Diagnostics is gearing up to commercialize a liquid biopsy test that applies methylation biomarkers to detect lung cancer, based on data presented at the International Association for the Study of Lung Cancer 2020 World Conference for Lung Cancer (WCLC) last month. The Seville-based firm also expects to release clinical data on its next ...
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...